Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1748-1757

  Adjei, Alex A ^a   Erlichman, Charles ^a   Sloan, Jeff A ^a   Reid, Joel M ^a   Pitot, Henry C ^a   Goldberg, Richard M ^a   Peethambaram, Prema ^a   Atherton, Pamela ^a   Hanson, Lorelei J ^a   Alberts, Steven R ^a   Jett, James ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GEMCITABINE; GRANISETRON; ONDANSETRON; PEMETREXED;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG CANCER; MALE; MESOTHELIOMA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RASH; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

EID: 0033993714     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1748     Document Type: Article

References (21)

1. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10, 1995 (suppl 11)
2. Guchelaar HJ, Richel DJ, van Knapen A: Clinical, toxicological and pharmacologic aspects of gemcitabine. Cancer Treat Rev 22:15-31, 1996
3. Rajkumar V, Adjei AA: A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev 24:35-53, 1998
4. Grindley GB, Shih C, Barnett C, et al: LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33:411, 1992 (abstr)
5. Schilsky RL: Antimetabolites, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, 1992, pp 301-315
6. Shih C, Gosset L, Gates S, et al: LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): Multiple folate enzyme inhibition. Ann Oncol 7:85, 1996 (suppl 1)
7. Schultz R, Andis S, Chen V, et al: Comparative antitumor activity of the multitargeted antifolate LY231514 and the thymidylate synthase inhibitor ZD1694. Ann Oncol 7:85, 1996 (suppl 1)
8. Chen VJ, Bawley JR, Gossett L, et al: Activity of LY231514 against several enzymes in the folate-dependent pathways. Proc Am Assoc Cancer Res 37:2598, 1996 (abstr)
9. Chen VJ, Bewley JR, Andis SL, et al: Cellular pharmacology of MTA: A correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol 26:48-54, 1999 (suppl 6)
10. Schultz RM, Chen VJ, Bewley JR, et al: Biological activity of the multitargeted antifolate, MTA (LY231514) in human cell lines with different resistant mechanisms to antifolate drugs. Semin Oncol 26:68-73, 1999 (suppl 6)
11. Rinaldi DA, Burris HA, Dott FA, et al: A phase I evaluation of LY231514, a novel multi-targeted antifolate, administered every 21 days, Proc Am Soc Clin Oncol 15:1559, 1996 (abstr)
12. Clarke S, Boyer M, Millward, et al: Phase II study of LY231514 in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:465a, 1997 (abstr 1670)
13. Rusthoven J, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: A phase II study. J Clin Oncol 17:1194-1199, 1999
14. Cripps MC, Bunell M, Jollivet J, et al: Phase II study of a multi-targeted antifolate (LY231514) as first line therapy in patients with locally advanced or metastatic colorectal cancer (MCC). Eur J Cancer 33:S172, 1997 (suppl 8)
15. Calvert AH, Walling JM: Clinical studies with MTA. Br J Cancer 78:35-40, 1998 (suppl 3)
16. Paz-Ares L, Tabernero J, Moyano A, et al: A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Proc Am Soc Clin Oncol 17:339a, 1998 (abstr 1307)
17. Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22:27-55, 1984
18. Adjei AA, Budihardjo I, Rowinsky EK, et al: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal. Clin Cancer Res 3:761-770, 1997
19. Mullany S, Svingen PA, Kaufmann SH, et al: Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: Elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 42:391-399, 1998
20. Ratain MJ, Mick R, Schilsky R, et al: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637-1643, 1993
21. Chaudhary AK, Schannen V, Knadler MP, et al: Analysis of LY231514 by LC/MS/MS. The 47th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX, June 13-18, 1999